A prospective study of total homocysteine and pooled cardiovascular disease outcomes in the Irbesartan Type 2 Diabetic Nephropathy Trial Cohort.

被引：0
|
作者：
Bostom, A
Friedman, A
Hunsicker, L
Jacques, P
Selhub, J
机构：
[1] Rhode Isl Hosp, Providence, RI USA
[2] Indiana Univ, Indianapolis, IN 46204 USA
[3] Univ Iowa, Iowa City, IA USA
[4] Tufts Human Nutr Res Ctr, Vitamin Bioavailabil Lab, Boston, MA USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2003年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：672A / 672A
页数：1
相关论文
共 50 条
  • [1] A prospective study of C-Reactive Protein and pooled cardiovascular disease outcomes in the irbesartan type 2 diabetic nephropathy trial cohort.
    Bostom, A
    Friedman, A
    Hunsicker, L
    Jacques, P
    Selhub, J
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 672A - 672A
  • [2] Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy
    Berl, T
    Hunsicker, LG
    Lewis, JB
    Pfeffer, MA
    Porush, JG
    Rouleau, JL
    Drury, PL
    Esmatjes, E
    Hricik, D
    Parikh, CR
    Raz, I
    Vanhille, P
    Wiegmann, TB
    Wolfe, BM
    Locatelli, F
    Goldhaber, SZ
    Lewis, EJ
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 138 (07) : 542 - 549
  • [3] Cardiovascular outcomes in the irbesartan diabetic nephropathy trial (IDNT) of patients with type 2 diabetes and overt nephropathy.
    Berl, T
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 651A - 651A
  • [4] Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial
    Berl, T
    Hunsicker, LG
    Lewis, JB
    Pfeffer, MA
    Porush, JG
    Rouleau, JL
    Drury, PL
    Esmatjes, E
    Hricik, D
    Pohl, M
    Raz, I
    Vanhille, P
    Wiegmann, TB
    Wolfe, BM
    Locatelli, F
    Goldhaber, SZ
    Lewis, EJ
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (07): : 2170 - 2179
  • [5] Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy
    Friedman, AN
    Hunsicker, LG
    Selhub, J
    Bostom, AG
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (11): : 3397 - 3402
  • [6] The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics
    Rodby, RA
    Rohde, RD
    Clarke, WR
    Hunsicker, LG
    Anzalone, DA
    Atkins, RC
    Ritz, E
    Lewis, EJ
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (04) : 487 - 497
  • [7] Visit-to-Visit Variability in Blood Pressure and Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Nephropathy: A Post Hoc Analysis From the RENAAL Study and the Irbesartan Diabetic Nephropathy Trial
    McMullan, Ciaran J.
    Heerspink, Hiddo J. Lambers
    Parving, Hans-Henrik
    Dwyer, Jamie P.
    Forman, John P.
    de Zeeuw, Dick
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 64 (05) : 714 - 722
  • [8] Proteinuria as a predictor of total plasma homocysteine levels in type 2 diabetic nephropathy
    Friedman, AN
    Hunsicker, LG
    Selhub, J
    Bostom, AG
    [J]. DIABETES CARE, 2002, 25 (11) : 2037 - 2041
  • [9] Neopterin as an Effect Modifier of the Cardiovascular Risk Predicted by Total Homocysteine: A Prospective 2-Cohort Study
    Bjornestad, Espen O.
    Borsholm, Robert A.
    Svingen, Gard F. T.
    Pedersen, Eva R.
    Seifert, Reinhard
    Midttun, Oivind
    Ueland, Per M.
    Tell, Grethe S.
    Bonaa, Kaare H.
    Nygard, Ottar
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (11):
  • [10] Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients - A prospective study
    Bostom, AG
    Shemin, D
    Verhoef, P
    Nadeau, MR
    Jacques, PF
    Selhub, J
    Dworkin, L
    Rosenberg, IH
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) : 2554 - 2558
12345